RESEARCH ARTICLE

VEGF-C and VEGF-D Expression and its Correlation with Lymph Node Metastasis in Esophageal Squamous Cell Cancer Tissue

Zeng Yang1*, Yong-Gang Wang2, Kai Su2

Abstract

**Background:** To explore vascular endothelial growth factor C (VEGF-C) and VEGF-D expression and its correlation with lymph node metastasis in esophageal squamous cell cancer (ESCC) tissue. **Materials and Methods:** Immunohistochemical methods were applied to detect the levels of VEGF-C and VEGF-D expression in 64 surgically removed ESCC tissues, tissues adjacent to cancer and normal tissues, and the relationship between VEGF-C and VEGF-D expression and lymph node metastasis was analyzed. **Results:** Both VEGF-C and VEGF-D were expressed by varying degrees in esophageal cancer tissue, the tissue adjacent to cancer and normal tissue, and the positive expression rate went down successively. The positive expression rates of VEGF-C (59.4%) and VEGF-D (43.8%) in esophageal cancer tissue were significantly higher than in the tissue adjacent to cancer (34.4%, 15.6%) and normal tissue (20.3%, 12.5%), respectively, in which significant differences were manifested \( p < 0.01 \). Positive expression rates of VEGF-C and VEGF-D in esophageal cancers with lymph node metastasis were markedly higher than without such metastasis \( (p < 0.01) \), while those in the tissue with TNM staging I–II were markedly lower than that with TNM staging III–IV \( (p < 0.01) \). **Conclusions:** Both VEGF-C and VEGF-D are highly expressed in ESCC tissue, which may be related to the lymph node metastasis of cancer cells. Hence, VEGF-C and VEGF-D can be clinically considered as important reference indexes of lymph node metastasis in esophageal cancer.

**Keywords:** Esophageal SCC - vascular endothelial growth factor C - VEGF D - lymph node metastasis

Introduction

The important malignant behavior of esophageal cancer is lymph node metastasis of cancer cells through lymphatic ducts, whereas the lymph node metastasis directly affects treatment methods, local recurrence and long-term survival. In recent years, studies on lymphangiogenesis mechanism and regulatory factors in cancer tissue have been a hotspot in tumor research. Some studies have revealed that vascular endothelial growth factor C (VEGF-C) promotes the lymphangiogenesis by action on its corresponding receptor VEGFR-3 (Chang et al., 2014; Omoto et al., 2014). VEGF-D, a sort of expressive secretory dimer glycoprotein induced by C-FOS gene, is a lately-discovered growth factor of lymphatic ducts, which can promote tumor lymphangiogenesis and is intimately related to lymphatic metastasis of tumor cells (Sun et al., 2012; He et al., 2013). At present, there are few studies on VEGF-C and VEGF-D expression in esophageal cancer, especially on the lymph node metastasis of esophageal cancer. Hence, this study detected VEGF-C and VEGF-D expression in esophageal squamous cell cancer (ESCC) tissue and investigated its relationship with lymph node metastasis so as to provide new ideas for early diagnosis, blocking tumor cell infiltration and metastasis of esophageal cancer.

Materials and Methods

**General materials**

Sixty-four patients with complete clinical and pathological files who underwent ESCC radical operation in Cancer Hospital were collected from Jun., 2012 to Jun. 2014. Before operation, all patients were not given radiotherapy, chemotherapy and immunotherapy. There were 44 males and 20 females at the age of 42–74, with the median age of 65. Thirty cases encountered lymph node metastasis, 34 cases not. High, middle and low differentiation were 14, 33 and 17 cases, respectively. According to infiltration depth, there were 15, 17, 24 and 8 cases at T1, T2, T3 and T4, respectively. All samples were fixed by 10% neural formalin, dehydrated routinely, embedded by paraffin, cut into 4 μm slices and confirmed by pathological histology. Specific methods for collecting
Materials: i) normal tissue: the incisal edge more than 5 cm far away from cancer lesion edge; ii) esophageal cancer tissue: the tissue from cancer lesion edge to the inside; iii) tissue adjacent to cancer: the tissue 2 cm away from cancer lesion edge to the outside.

Both VEGF-C and VEGF-D polyclonal antibodies were purchased from American Santa Cruz Company, trypsin and ready-to-use SABC immunohistochemical staining kits from Beijing Zhongshan Biotechnology Co., Ltd, the working solution of immunohistochemical secondary antibodies and DAB kits from Shanghai Changdao Biological Reagent Company.

Methods

Under the working concentration of 1:50, VEGF-C was conducted antigen retrieval at 37°C for 10 min through trypsin. Under the working concentration of 1:100, VEGF-D was repaired at high pressure for 5 min by 0.01 mol/L citrate buffer solution (pH=4.0). All primary antibodies stayed overnight at 4°C, and the working solution of secondary antibodies was incubated in an incubator at 37°C for 30 min. DAB and hematoxylin were respectively used for coloration and counterstaining. Phosphate buffer solution (PBS) was regarded as negative control instead of primary antibodies, and the known positive sections as positive control. Additionally, the staining procedures were performed according to SABC kit instructions.

Result evaluation

Evaluation on VEGF-C and VEGF-D immunohistochemical results: Under high power lens (×200), 5 visual fields were randomly observed in each piece of section. At first, the points were scored (0 point: hardly coloration; 1 point: canary; 2 points: claybank; 3 points: sepia) according to specific staining degrees emerging from the cytoplasm. Next, the points were scored again (0 point: colored cell number<1%; 1 point: colored cell number being 1%~10%; 2 points: colored cell number being 11%~50%; 3 points: colored cell number >50%) according to the percentage of colored cells occupying cell count. At last, the product of these two items was immunohistochemical score of one case, in which 0~2, 3~4, 5~7 and 8~9 points mean point of 5 visual fields was immumohistochemical point of this visual field, and the cell count. At last, the product of these two items was calculated according to the percentage of colored cells occupying cell count. The strongly-positive expression rate was redefined as (+++) expression rate conspicuously higher than in normal tissue (p<0.05 or p<0.01), and the moderately-positive expression rate conspicuously higher than in normal tissue (p<0.05). However, there was no significant difference by comparison to its weakly-positive (+) expression rates in three groups (p>0.05) (Table 1).

Table 1. Comparison of VEGF-C Expression in three Tissues [n(%)]

<table>
<thead>
<tr>
<th>Groups</th>
<th>-</th>
<th>+</th>
<th>++</th>
<th>+++</th>
<th>Positive rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esophageal carcinoma</td>
<td>26 (40.63)</td>
<td>7 (10.94)</td>
<td>18 (28.13)</td>
<td>13 (20.31)***</td>
<td>59.38***</td>
</tr>
<tr>
<td>Tissue adjacent to carcinoma</td>
<td>42 (65.63)</td>
<td>6 (9.36)</td>
<td>12 (18.75)</td>
<td>4 (6.25)</td>
<td>34.37</td>
</tr>
<tr>
<td>Normal tissue</td>
<td>51 (87.50)</td>
<td>4 (6.25)</td>
<td>7 (10.94)</td>
<td>2 (3.13)</td>
<td>20.29</td>
</tr>
</tbody>
</table>

Compared with the tissue adjacent to cancer, *p<0.05, **p<0.01; Compared with normal tissue, *p<0.05, **p<0.01

Table 2. Comparison of VEGF-D Expression in three Tissues [n(%)]

<table>
<thead>
<tr>
<th>Groups</th>
<th>-</th>
<th>+</th>
<th>++</th>
<th>+++</th>
<th>Positive rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Esophageal carcinoma</td>
<td>36(56.25)</td>
<td>6(9.36)</td>
<td>13(20.31)**</td>
<td>9(14.06)**</td>
<td>43.75***</td>
</tr>
<tr>
<td>Tissue adjacent to carcinoma</td>
<td>54(84.38)</td>
<td>6(9.36)</td>
<td>3(4.69)</td>
<td>1(1.56)</td>
<td>15.63</td>
</tr>
<tr>
<td>Normal tissue</td>
<td>56(87.50)</td>
<td>5(7.81)</td>
<td>2(3.13)</td>
<td>1(1.56)</td>
<td>12.50</td>
</tr>
</tbody>
</table>

Compared with the tissue adjacent to cancer, **p<0.01; Compared with normal tissue, *p<0.01.
Correlation between VEGF-C, VEGF-D expression and lymph node metastasis

The positive expression rates of VEGF-C and VEGF-D in the tissue with lymph node metastasis were notably higher than that without lymph node metastasis, while those in the tissue with TNM staging being 1-II markedly lower than that with TNM staging being III-IV. Both differences had statistical significance (p<0.01) (Table 3).

Discussion

As one of clinical commonly-encountered malignant tumors, esophageal cancer threatens the human health seriously. Lymphatic drainage directly enters into thoracic ducts through regional lymph nodes because there is no serosa, but abundant lymphatic drainage in esophageal walls, which makes esophageal caner occur lymph node metastasis at an early stage. A lot of studies indicated that the survival rate of patients with lymph node metastasis was evidently lower than that without lymph node metastasis (Feng et al., 2013; Hsu et al., 2013; Sui et al., 2014). Therefore, it is of great importance to research the lymphatic metastasis mechanism of cancer cells.

It is found that lymphangiogenesis is related to lymphatic metastasis with further studies made. In recent years, the regulatory factor VEGF which is associated with lymphangiogenesis has been a hotspot. As one member of platelet-derived growth factor family, VEGF is the most important vascular endothelial growth stimulating factor in the process of tumor angiogenesis. There are a few studies that have demonstrated that the growth factors of lymphatic ducts (VEGF-C and VEGF-D) and its generation are related to cancer metastasis and poor prognosis (Jiang et al., 2012; Karaman et al., 2014). By expressing VEGF-C and VEGF-D, tumor cells can induce lymphangiogenesis and promote lymphatic metastasis. VEGF-C, a new member of VEGF family, is expressed in most of tumors. It can promote endothelial cell proliferation and increase vascular permeability. As a key factor of tumor angiogenesis, infiltration and metastasis, VEGF-C has a special function in enhancing lymphangiogenesis (Kostis et al., 2014). Being highly homologous with VEGF-C, VEGF-D overexpression in dermal keratinocytes has the effect of lymphangiogenesis (Trompeziński et al., 2004). With the action of paracrine mode, VEGF-D makes receptors autophosphorylation by VEGF-D/VEGFR-3 pathways, stimulates lymphatic endothelial cell proliferation and migration of tumors and promotes lymphangiogenesis through the signal transduction in cytoplasm, consequently increasing the incidence of lymphatic metastasis of tumors. The research confirmed that VEGF-D could not only induce lymphangiogenesis in tumor tissues, but also cause the tumor cell diffusion to regional lymph nodes (Kawai et al., 2003; Harris et al., 2013).

This study adopted immunohistochemical method to detect VEGF-C and VEGF-D expression in esophageal cancer tissue, tissue adjacent to cancer and normal tissue, and the results showed that both VEGF-C and VEGF-D were expressed differently in esophageal cancer tissue, tissue adjacent to cancer and normal tissue. The positive reaction of VEGF-C primarily occurred in cytoplasm of tumor cells, while that of VEGF-D mainly in cytoplasm of tumor cells or normal epithelial cells. Both positive and strongly-positive expression rates of VEGF-C in esophageal cancer were markedly higher than in the tissue adjacent to cancer and normal tissue, and moderately-positive expression rate conspicuously higher than in normal tissue and slightly higher than in the tissue adjacent to cancer, indicating that VEGF-C is highly expressed in esophageal cancer tissue, and expression intensities (moderately and strongly positive) are higher than in the tissue adjacent to cancer and normal tissue. The positive, strongly and moderately-positive expression rates of VEGF-D in esophageal cancer were significantly higher than in the tissue adjacent to cancer and normal tissue, illustrating that VEGF-D is highly expressed in esophageal cancer tissue, and expression intensities (moderately and strongly positive) are higher than in the tissue adjacent to cancer and normal tissue. Additionally, the positive expression rates of VEGF-C and VEGF-D in the tissue with lymph node metastasis were notably higher than that without lymph node metastasis, while those in the tissue with TNM staging being 1-II markedly lower than that with TNM staging being III-IV, suggesting that high expression of VEGF-C and VEGF-D may be related to the lymph node metastasis and clinical staging of esophageal cancer.

To sum up, both VEGF-C and VEGF-D are highly expressed in esophageal cancer tissue, which may be associated with the lymph node metastasis and clinical staging of esophageal cancer. Hence, high expression of VEGF-C and VEGF-D can be considered as important reference indexes of lymph node metastasis in esophageal cancer, whereas it clinically manifests to be related to TNM staging.

References

Harris NC, Davydova N, Roufail S, et al (2013). The propeptides of VEGF-D determine heparin binding, receptor
Zeng Yang et al.


